EA201692150A1 - Способ лечения аденокарциномы легкого - Google Patents

Способ лечения аденокарциномы легкого

Info

Publication number
EA201692150A1
EA201692150A1 EA201692150A EA201692150A EA201692150A1 EA 201692150 A1 EA201692150 A1 EA 201692150A1 EA 201692150 A EA201692150 A EA 201692150A EA 201692150 A EA201692150 A EA 201692150A EA 201692150 A1 EA201692150 A1 EA 201692150A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ros1
treatment
patient
lung adenocarcinoma
cancer
Prior art date
Application number
EA201692150A
Other languages
English (en)
Other versions
EA035223B1 (ru
Inventor
Дана Т. Афтаб
Пэйвэнь Юй
Original Assignee
Экселиксис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53055132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201692150(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Экселиксис, Инк. filed Critical Экселиксис, Инк.
Publication of EA201692150A1 publication Critical patent/EA201692150A1/ru
Publication of EA035223B1 publication Critical patent/EA035223B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к лечению рака у пациента, в частности у пациента с аденокарциномой легкого и более конкретно у пациента с немелкоклеточным раком легкого, позитивным по слиянию SLC34A2-ROS1, CD74-ROS1 или FIG-ROS1, с помощью ингибитора MET, VEGFR2 и ROS1, который представляет собой соединение формулы Iили его фармацевтически приемлемую соль.
EA201692150A 2014-04-25 2015-04-27 Способ лечения немелкоклеточного рака легкого EA035223B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984599P 2014-04-25 2014-04-25
PCT/US2015/027800 WO2015164869A1 (en) 2014-04-25 2015-04-27 Method of treating lung adenocarcinoma

Publications (2)

Publication Number Publication Date
EA201692150A1 true EA201692150A1 (ru) 2017-02-28
EA035223B1 EA035223B1 (ru) 2020-05-18

Family

ID=53055132

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692150A EA035223B1 (ru) 2014-04-25 2015-04-27 Способ лечения немелкоклеточного рака легкого

Country Status (21)

Country Link
US (1) US20170042880A1 (ru)
EP (2) EP3906921A1 (ru)
JP (2) JP6696908B2 (ru)
KR (1) KR102474701B1 (ru)
CN (1) CN106488768A (ru)
AR (1) AR100191A1 (ru)
AU (1) AU2015249232B2 (ru)
BR (1) BR112016024672A2 (ru)
CA (1) CA2946416C (ru)
DK (1) DK3134084T3 (ru)
EA (1) EA035223B1 (ru)
ES (1) ES2874875T3 (ru)
HU (1) HUE054557T2 (ru)
IL (1) IL248408B (ru)
MX (1) MX2016013600A (ru)
PL (1) PL3134084T3 (ru)
PT (1) PT3134084T (ru)
SG (1) SG11201608657QA (ru)
TW (1) TWI724988B (ru)
UA (1) UA121655C2 (ru)
WO (1) WO2015164869A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029506B1 (ru) 2011-05-02 2018-04-30 Экселиксис, Инк. Способ лечения рака и раковой боли в костях
MA39735A (fr) 2014-03-17 2017-01-25 Exelixis Inc Dosage de préparations de cabozantinib
US11124481B2 (en) 2014-07-31 2021-09-21 Exelixis, Inc. Method of preparing fluorine-18 labeled Cabozantinib and its analogs
CA2957466C (en) 2014-08-05 2023-10-17 Exelixis, Inc. Drug combinations to treat multiple myeloma
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN107353246A (zh) * 2016-12-27 2017-11-17 辅仁药业集团熙德隆肿瘤药品有限公司 一种制备抗肿瘤药物卡博替尼的方法
US11505830B2 (en) 2017-05-31 2022-11-22 Roche Molecular Systems, Inc. Multiplex PCR detection of ALK, RET, and ROS fusions
CN110678180A (zh) 2017-06-09 2020-01-10 埃克塞里艾克西斯公司 治疗癌症的液体剂型
CN107541550A (zh) * 2017-08-21 2018-01-05 上海派森诺生物科技股份有限公司 人ros1融合基因检测方法
US11596694B2 (en) * 2017-09-20 2023-03-07 Mersana Therapeutics, Inc. Compositions and methods for predicting response to NaPi2b-targeted therapy
CN111936487A (zh) * 2018-01-26 2020-11-13 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
CA3088127A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN117603138A (zh) 2018-01-26 2024-02-27 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
DE102020005002A1 (de) * 2020-08-17 2022-02-17 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Mittel zur Therapie von Tumorerkrankungen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
ES2925655T3 (es) * 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
US20100143918A1 (en) 2007-01-19 2010-06-10 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
JP5769968B2 (ja) 2007-10-18 2015-08-26 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト非小細胞肺癌における転座および変異ｒｏｓキナーゼ
TWI447108B (zh) * 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
US9364477B2 (en) 2009-02-12 2016-06-14 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
TWI585088B (zh) * 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
US20150238477A1 (en) 2012-09-07 2015-08-27 Exelixis, Inc. Method of Treating Lung Adenocarcinoma

Also Published As

Publication number Publication date
EP3134084B1 (en) 2021-03-17
EP3134084A1 (en) 2017-03-01
PL3134084T3 (pl) 2021-09-27
KR102474701B1 (ko) 2022-12-05
AU2015249232A1 (en) 2016-11-10
IL248408B (en) 2022-06-01
IL248408A0 (en) 2016-11-30
MX2016013600A (es) 2017-04-27
US20170042880A1 (en) 2017-02-16
CA2946416C (en) 2022-07-19
AU2015249232B2 (en) 2020-06-25
JP2019189646A (ja) 2019-10-31
DK3134084T3 (da) 2021-05-03
ES2874875T3 (es) 2021-11-05
HUE054557T2 (hu) 2021-09-28
TWI724988B (zh) 2021-04-21
SG11201608657QA (en) 2016-11-29
UA121655C2 (uk) 2020-07-10
AR100191A1 (es) 2016-09-14
EA035223B1 (ru) 2020-05-18
CA2946416A1 (en) 2015-10-29
EP3906921A1 (en) 2021-11-10
WO2015164869A1 (en) 2015-10-29
CN106488768A (zh) 2017-03-08
JP6696908B2 (ja) 2020-05-20
PT3134084T (pt) 2021-05-11
JP2017513908A (ja) 2017-06-01
TW201622723A (zh) 2016-07-01
NZ725576A (en) 2021-03-26
KR20160147934A (ko) 2016-12-23
BR112016024672A2 (pt) 2021-02-02

Similar Documents

Publication Publication Date Title
EA201692150A1 (ru) Способ лечения аденокарциномы легкого
CY1123631T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
ECSP16083602A (es) Derivados de quinolina como inhibidores smo
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201591509A1 (ru) Ингибиторы cdc7
NZ758528A (en) Bicyclic heterocycle compounds and their uses in therapy
EA201391114A1 (ru) Способы использования alk-ингибиторов
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
EA201892486A1 (ru) Способ получения соединения диарилтиогидантоина
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
EA201692534A1 (ru) Способы лечения гипотонии
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
MX2016004967A (es) Tratamiento para cancer pancreatico.
EA201690075A1 (ru) Способ лечения внутриклеточной инфекции
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
EA201692332A1 (ru) Борсодержащие ингибиторы протеасом для применения после первичной противораковой терапии
EA201590656A1 (ru) Азаиндолины
EA201891008A3 (ru) Лечение симптомов, связанных с андроген-депривационной терапией

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM